HK1206259A1 - 寡核苷酸螯合物方法 - Google Patents

寡核苷酸螯合物方法

Info

Publication number
HK1206259A1
HK1206259A1 HK15106885.8A HK15106885A HK1206259A1 HK 1206259 A1 HK1206259 A1 HK 1206259A1 HK 15106885 A HK15106885 A HK 15106885A HK 1206259 A1 HK1206259 A1 HK 1206259A1
Authority
HK
Hong Kong
Prior art keywords
chelate complex
complex methods
oligonucleotide chelate
oligonucleotide
methods
Prior art date
Application number
HK15106885.8A
Other languages
English (en)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of HK1206259A1 publication Critical patent/HK1206259A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
HK15106885.8A 2012-05-18 2015-07-20 寡核苷酸螯合物方法 HK1206259A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648694P 2012-05-18 2012-05-18
PCT/CA2013/050378 WO2013170385A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex methods

Publications (1)

Publication Number Publication Date
HK1206259A1 true HK1206259A1 (zh) 2016-01-08

Family

ID=49581827

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106885.8A HK1206259A1 (zh) 2012-05-18 2015-07-20 寡核苷酸螯合物方法

Country Status (37)

Country Link
US (1) US9616083B2 (zh)
EP (1) EP2849760B1 (zh)
JP (2) JP6294308B2 (zh)
KR (1) KR101975915B1 (zh)
CN (1) CN104379152B (zh)
AR (1) AR091065A1 (zh)
AU (1) AU2013262415B2 (zh)
BR (1) BR112014028568B1 (zh)
CA (1) CA2873526C (zh)
CL (1) CL2014003135A1 (zh)
CO (1) CO7131388A2 (zh)
CR (1) CR20140522A (zh)
CU (1) CU20140132A7 (zh)
CY (1) CY1122856T1 (zh)
DK (1) DK2849760T3 (zh)
DO (1) DOP2014000263A (zh)
EA (1) EA034799B1 (zh)
EC (1) ECSP14027542A (zh)
ES (1) ES2767333T3 (zh)
HK (1) HK1206259A1 (zh)
HR (1) HRP20200045T1 (zh)
HU (1) HUE047456T2 (zh)
IL (1) IL235402B (zh)
IN (1) IN2014DN08982A (zh)
LT (1) LT2849760T (zh)
MX (1) MX360626B (zh)
MY (1) MY168209A (zh)
NZ (1) NZ701931A (zh)
PH (1) PH12014502484B1 (zh)
PL (1) PL2849760T3 (zh)
PT (1) PT2849760T (zh)
RS (1) RS59914B1 (zh)
SG (1) SG11201407261XA (zh)
SI (1) SI2849760T1 (zh)
TW (1) TWI648288B (zh)
WO (1) WO2013170385A1 (zh)
ZA (1) ZA201408082B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
KR102025679B1 (ko) 2012-08-30 2019-09-26 레플리코르 인코포레이티드 Ｂ형 간염 및 ｄ형 간염 감염증의 치료 방법
RS60645B1 (sr) 2015-04-23 2020-09-30 Geron Corp Postupci za pripremu polinukleotida upotrebom kompozicija multivalentne katjonske soli
CA3000931A1 (en) 2015-10-28 2017-05-04 Crispr Therapeutics Ag Materials and methods for treatment of duchenne muscular dystrophy
JP7412079B2 (ja) 2015-12-23 2024-01-12 レプルカ プロプライアタリー リミティド 核酸オリゴマーとその用途
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2022229350A2 (en) 2021-04-30 2022-11-03 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0691853B1 (en) * 1993-04-01 2002-06-05 Isis Pharmaceuticals, Inc. ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION
US20020166764A1 (en) 1997-08-12 2002-11-14 University Of Southern California Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CN1694959A (zh) * 2002-09-13 2005-11-09 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
EA008940B1 (ru) * 2002-09-13 2007-10-26 Репликор, Инк. Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
EP1802643A1 (en) * 2004-10-19 2007-07-04 Replicor Inc. Antiviral oligonucleotides
CA2624686A1 (en) 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
CA2660052A1 (en) * 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of jnk proteins
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
US8361980B2 (en) 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
US9107933B2 (en) 2009-03-16 2015-08-18 Isis Pharmaceuticals, Inc. Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
EP2435571B1 (en) * 2009-05-28 2016-12-14 CuRNA, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
SI2605794T1 (sl) 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi

Also Published As

Publication number Publication date
CR20140522A (es) 2014-12-10
JP2015517503A (ja) 2015-06-22
DK2849760T3 (da) 2020-02-03
US20130310445A1 (en) 2013-11-21
SG11201407261XA (en) 2014-12-30
PH12014502484A1 (en) 2015-01-12
WO2013170385A1 (en) 2013-11-21
IL235402A0 (en) 2014-12-31
HUE047456T2 (hu) 2020-04-28
EA034799B1 (ru) 2020-03-23
RS59914B1 (sr) 2020-03-31
EP2849760A4 (en) 2015-03-25
CN104379152A (zh) 2015-02-25
MY168209A (en) 2018-10-15
KR101975915B1 (ko) 2019-05-08
TWI648288B (zh) 2019-01-21
AU2013262415A1 (en) 2014-11-27
CN104379152B (zh) 2018-10-30
LT2849760T (lt) 2020-04-10
JP2018058853A (ja) 2018-04-12
ES2767333T3 (es) 2020-06-17
CL2014003135A1 (es) 2015-01-09
ECSP14027542A (es) 2015-12-31
CU20140132A7 (es) 2015-02-26
PH12014502484B1 (en) 2015-01-12
HRP20200045T1 (hr) 2020-03-20
PL2849760T3 (pl) 2020-05-18
SI2849760T1 (sl) 2020-03-31
IN2014DN08982A (zh) 2015-05-22
EA201401276A1 (ru) 2015-04-30
TW201408689A (zh) 2014-03-01
MX2014013885A (es) 2015-05-08
AU2013262415B2 (en) 2017-06-22
DOP2014000263A (es) 2015-01-31
CY1122856T1 (el) 2021-05-05
ZA201408082B (en) 2015-12-23
CO7131388A2 (es) 2014-12-01
IL235402B (en) 2022-01-01
US9616083B2 (en) 2017-04-11
EP2849760A1 (en) 2015-03-25
MX360626B (es) 2018-11-12
BR112014028568A2 (pt) 2020-06-02
JP6294308B2 (ja) 2018-03-14
EP2849760B1 (en) 2019-10-30
PT2849760T (pt) 2020-01-24
AR091065A1 (es) 2014-12-30
CA2873526C (en) 2020-08-18
BR112014028568B1 (pt) 2022-02-15
CA2873526A1 (en) 2013-11-21
KR20150016330A (ko) 2015-02-11
NZ701931A (en) 2016-06-24

Similar Documents

Publication Publication Date Title
IL254716B (en) Zinc-lysine conjugate
HK1250690A1 (zh) 方法
DK2922554T3 (en) Terminalt modificeret rna
HK1208363A1 (zh) 新方法
HK1206259A1 (zh) 寡核苷酸螯合物方法
GB2507760B (en) Methods
ZA201408674B (en) Oligonucleotide chelate complex-polypeptide compositions and methods
EP2852660A4 (en) PROCESS
GB201208874D0 (en) Methods
EP2891717A4 (en) Oligonucleotide
GB201204280D0 (en) Methods
GB201208756D0 (en) Methods
GB201220686D0 (en) Methods
AP2012000550S (en) E-horn methods
GB201216074D0 (en) Methods
GB201209689D0 (en) Methods
GB201208875D0 (en) Methods
GB201208963D0 (en) Methods
GB201207793D0 (en) Methods
GB201209932D0 (en) Improved process
GB201202052D0 (en) Well cementation
GB201205665D0 (en) Process
GB201205052D0 (en) Process